MEDINET CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45 JPY | 0.00% |
|
0.00% | +4.65% |
| Sales 2017 | 1.7B 10.89M 907M | Sales 2018 | 998M 6.38M 531M | Capitalization | 10.17B 64.99M 5.41B |
|---|---|---|---|---|---|
| Net income 2017 | -2.6B -16.64M -1.39B | Net income 2018 | -3.05B -19.48M -1.62B | EV / Sales 2017 | 6.03 x |
| Net cash position 2017 | 3.31B 21.15M 1.76B | Net cash position 2018 | 2.13B 13.61M 1.13B | EV / Sales 2018 | 8.05 x |
| P/E ratio 2017 |
-4.7
x | P/E ratio 2018 |
-3.21
x | Employees | 92 |
| Yield 2017 * |
-
| Yield 2018 |
-
| Free-Float | 92.74% |
More Fundamentals
* Assessed data
More news
More press releases
| Current month | -13.46% | ||
| 1 month | -11.76% | ||
| 3 months | +2.27% | ||
| 6 months | +2.27% | ||
| Current year | +4.65% |
1 week
45.00
47.00
1 month
44.0051.00
Current year
42.0056.00
1 year
41.0072.00
3 years
39.00127.00
5 years
33.00179.00
10 years
33.00404.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yoshiji Kimura
FOU | Founder | 72 | 17/95/17 |
| President | 63 | 01/20/01 | |
Masazo Ochiai
ADM | Chief Administrative Officer | 49 | 01/04/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yoshiji Kimura
FOU | Founder | 72 | 17/95/17 |
| Director/Board Member | 75 | 01/18/01 | |
Takeshi Shinoda
BRD | Director/Board Member | 62 | 01/14/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 45 | 0.00% | 471,400 |
| 25/24/25 | 45 | -2.17% | 856,900 |
| 24/24/24 | 46 | 0.00% | 394,600 |
| 23/24/23 | 46 | 0.00% | 186,100 |
| 22/24/22 | 46 | +2.22% | 676,100 |
Delayed Quote Japan Exchange, April 26, 2024 at 11:30 am IST
More quotes
MEDINET Co., Ltd. is a Japan-based company mainly engaged in cell processing industry and cellular medical products business. It operates through two business segments. The Cell Processing Industry segment mainly engages in comprehensive support services for immune cell therapy, related services including clinical use from companies, universities, research institutes, outsourcing of cell processing for clinical trials and operation of cell culture processing facilities. The Cellular Medical Products segment is mainly engaged in research and development for obtaining approval for manufacture and marketing of cellular medical products. It also provides comprehensive support services for immune cell therapy.
Calendar
10/05/2024
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +4.65% | 73.24M | |
| +2.62% | 42.75B | |
| +47.70% | 41.61B | |
| +12.08% | 41.34B | |
| -8.83% | 26.59B | |
| +7.98% | 25.49B | |
| -22.45% | 18.12B | |
| +31.23% | 12.24B | |
| -1.37% | 11.76B | |
| +8.48% | 11B |
- Stock Market
- Equities
- 2370 Stock
